The KRAS tour: Studying metabolic reprogramming in isogenic pancreatic cancer organoids.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38181746.
- Also identified by DOI 10.1016/j.stem.2023.12.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Using an isogenic organoid platform to model pancreatic cancer, Duan et al. establish an important link between mutant KRAS and cholesterol metabolism and identify perhexiline maleate as a possible therapeutic to target this relationship.
Medical subject headings
- Metabolic Reprogramming
- Pancreatic Neoplasms